Trials / Completed
CompletedNCT06256094
The Effects of a2 Infant Formula on Growth and Tolerance in Healthy Term Infants
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 280 (actual)
- Sponsor
- a2 Milk Company Ltd. · Industry
- Sex
- All
- Age
- 60 Days – 120 Days
- Healthy volunteers
- Accepted
Summary
This is a randomized, open-label, prospective study to evaluate the nutritive effects of an a2 infant formula on growth and tolerance in healthy term infants. A total of 280 healthy, term, mixed-fed infants between 60 and 120 days of age were enrolled at Shanghai. The participants were randomly assigned to one of the two study groups: the a2 infant formula group and the conventional A1/A2 infant formula group. Each group contained 140 infants. The study duration was 56 days.
Detailed description
Primary objective: To compare the growth measurements of the infants fed with the a2 infant formula with those fed with conventional A1/A2 infant formula during the study period. Secondary objectives: To compare the two study groups in 1. Dermatitis quality of life 2. Formula tolerability and acceptability 3. All medically confirmed adverse events The study included four visits at day 0 (baseline), day 14, day 28 and day 56. Information of efficacy outcomes were collected at each visit. Subject diary was used to record tolerance data and daily formula feeding amount during the study. The parents of the participants were also required evaluate their satisfaction with the study formula at the last visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | a2 Platinum Premium Infant Formula Stage 1 | Oral intake of a2 Platinum Premium Infant Formula Stage 1 milk powder (dissolved in water) |
| DIETARY_SUPPLEMENT | Frisolac Infant Formula Stage 1 (Dutch Edition) | Oral intake of Frisolac Infant Formula Step 1 (Dutch Edition) milk power (dissolved in water) |
Timeline
- Start date
- 2023-07-14
- Primary completion
- 2023-11-03
- Completion
- 2023-11-03
- First posted
- 2024-02-13
- Last updated
- 2024-02-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06256094. Inclusion in this directory is not an endorsement.